Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups

Basit Öğe Kaydı
dc.authoridkisioglu, savas volkan/0000-0002-7742-048X
dc.authoridKOCAK, Mustafa/0000-0002-8269-2869
dc.authoridTUFEKCI, Damla/0000-0001-5928-873X
dc.authoridKARAKULLUKCU, SERDAR/0000-0001-7673-7699
dc.authorwosidkisioglu, savas volkan/AAT-3031-2021
dc.authorwosidKOCAK, Mustafa/B-3876-2012
dc.authorwosidEMUR GUNAY, YASEMIN/JEO-9371-2023
dc.contributor.authorGunay, Yasemin Emur
dc.contributor.authorKisioglu, Savas Volkan
dc.contributor.authorKarakullukcu, Serdar
dc.contributor.authorTufekci, Damla
dc.contributor.authorDemir, Ahmet Suat
dc.contributor.authorCoskun, Hulya
dc.contributor.authorNuhoglu, Irfan
dc.date.accessioned2024-05-19T14:46:04Z
dc.date.available2024-05-19T14:46:04Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractOBJECTIVE: The objective of this study was to examine the effects of orlistat use on metabolic control and weight loss in diabetic and nondiabetic patients.METHODS: A total of 119 patients with body mass index>_40 kg/m2and receiving orlistat therapy, who applied to the Endocrinology polyclinic between January 2016 and October 2019, were included. The patients' weight changes and biochemical values (i.e., fasting glucose, HbA1c, ALT, creatinine, and lipid parameters) were evaluated at the drug beginning and the last polyclinic control. The patients were divided into groups, whether they had diabetes or used metformin, and compared.RESULTS: The mean age of the 119 patients in the study was 45.3 & PLUSMN;11.5 years. A total of 94.1% of the patients were females and 5.9% were males. A total of 38.7% of the patients had diabetes and 29.4% had prediabetes. When the patients were compared to whether they had diabetes or used metformin, there was a statistically significant difference between the groups according to weight loss. The mean weight change of patients without diabetes and receiving metformin and orlistat was statistically significantly higher than that of patients with diabetes and receiving metformin and orlistat.DISCUSSION: It was determined that the weight loss effect of orlistat in obesity was seen in all groups, but this effect decreased in the diabetic group.en_US
dc.identifier.doi10.1590/1806-9282.20230174
dc.identifier.issn0104-4230
dc.identifier.issn1806-9282
dc.identifier.issue7en_US
dc.identifier.pmid37466599en_US
dc.identifier.scopus2-s2.0-85165519702en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1590/1806-9282.20230174
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5434
dc.identifier.volume69en_US
dc.identifier.wosWOS:001033719400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAssoc Medica Brasileiraen_US
dc.relation.ispartofRevista Da Associacao Medica Brasileiraen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectObesityen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectOrlistaten_US
dc.titleComparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groupsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu